
Sanofi has revealed that it will not discount its new insulin Toujeo more than its current blockbuster Lantus, despite lacking …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

